Impact of the Microbiome-Gut-Brain Axis on Alzheimer's Disease and Alzheimer's Disease-Related Dementias (R01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites applications for basic and translational research on the impact of the microbiome on Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD). While there is growing evidence that the microbiome is an important factor that contributes to overall health and a variety of diseases and disorders, the role of the alimentary canaland other sources of endogenous microbiota in specific AD/ADRDs has not been adequately addressed. This FOA will support mechanistic research focused on a more rigorous in-depth examination of the potential interactions between the microbiome and genetic and non-genetic molecular targets that influence AD/ADRD. It is expected that these studies will address the clinical relevance of the microbiome on disease initiation, progression, or modification, and will lead ultimately to better therapeutic interventions.


  • Letter of Intent Due Date(s): Thirty days prior to due date

  • Application Due Date: October 05, 2022

PAR-22-211 Expiration Date October 06, 2022

Agency Website



Amount Description

Application budgets are limited to $500,000 in direct costs per year and need to reflect the actual needs of the proposed project.

The maximum project period is 5 years.

Funding Type





Medical - Basic Science
Medical - Translational

External Deadline

October 5, 2022